Gene Polymorphism of IL17 and IL 23

Study Overview
=================
Brief Summary
-----------------
rates are in such considerable amount among large population base. The pathogenesis of COVID-19 implicates a potent inflammatory response, involving a complex group of mediators including interleukins. These pleiotropic cytokines are secreted at the region of inflammation and released into the circulation by a variety of different cell types, including macrophages, lymphocytes, endothelial cells, epithelial cells during sepsis and acute organ injuries. There has recently found a number of studies reporting that the cytokine storms take part in the course of COVID-19

Detailed Description
-----------------
Aim Of The Study To evaluate if there is an association between the IL-17, IL-23 gene polymorphism in Patients With COVID 19 by real-time PCR To measure the serum level of IL17 by ELISA in COVID 19 patients by ELISA. To detect if there is an association between gene polymorphism of IL17 and IL23 and severity of a condition in patients with COVID 19 Study design: a cross-sectional study. The blood samples will be collected from patient records in COVID19 isolation hospitals in sohag governorate and isolation department in sohag university hospitals.

Official Title
-----------------
Association Between Gene Polymorphism of IL17 and IL 23 in Patients With COVID 19

Conditions
-----------------
COVID-19 Respiratory Infection

Intervention / Treatment
-----------------
* Diagnostic Test: laboratory test
* Diagnostic Test: laboratory test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Covid19 positive PCR Exclusion Criteria: Patients with Covid19 clinical criteria not confirmed by PCR
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group 1 patients with severe covid 19 respiratory infections<br>Patients with severe covid 19 admitted to ICU, blood samples will be collected for testing different genotypes and serum level of IL 17 | Diagnostic Test: laboratory test<br>* genotyping of IL 17 and IL23<br>Diagnostic Test: laboratory test<br>* estimation of serum level of IL 17<br>|
| group 2 patients with non severe covid 19 respiratory infections<br>Patients with nonsevere covid 19 admitted to the internal ward, blood samples will be collected for testing different genotypes and serum level of IL 17 | Diagnostic Test: laboratory test<br>* genotyping of IL 17 and IL23<br>Diagnostic Test: laboratory test<br>* estimation of serum level of IL 17<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| genotyping of IL 17 | real time pcr detection of different genotypes | 3-6-2021 to 30-8-2021 | 
| genotyping of IL 23 | real time pcr detection of different genotypes | 3-6-2021 to 30-8-2021 | 
| estimation of serum level of IL 17 | measuring serum level of IL 17 by ELISA | 3-6-2021 to 30-8-2021 |